文献速递淋巴瘤

Castleman病亚型特异性结局与管理的综合分析:一项20年队列研究

Comprehensive analysis of subtype-specific outcomes and management in Castleman disease: a 20-year cohort study.
PubMed 文献 · Blood Adv · 2026-01-01

该研究回顾性分析了2004年1月至2024年8月在本机构评估的217例Castleman病患者,比较不同亚型的生存结局。结果显示57%为单中心型、20%为寡中心型、23%为特发性多中心型;寡中心型与特发性多中心型的无事件生存期显著短于单中心型。研究验证了寡中心型和特发性多中心型-浆细胞型作为新亚型,寡中心型生存结局介于单中心型与多中心型之间,仅部分寡中心型患者需要全身治疗。

要点

  • 217例Castleman病中单中心型占57%、寡中心型占20%、特发性多中心型占23%。
  • 寡中心型和特发性多中心型的无事件生存期分别为8.9年和2.3年,均显著短于单中心型(未达到,P<.001和P<.02)。
  • 特发性多中心型-浆细胞型的无事件生存期长于特发性多中心型-TAFRO(P=.02),随访期间无死亡。

核心结论

  • 本研究验证了寡中心型和特发性多中心型-浆细胞型作为新的Castleman病亚型。
  • 寡中心型的生存结局介于单中心型和特发性多中心型之间,仅部分寡中心型患者需要全身治疗。
  • 特发性多中心型-浆细胞型在美国队列中生存结局良好,与非西方国家报道相似。
  • 根据疾病亚型制定治疗策略并警惕寡中心型进展可能改善Castleman病患者的生存结局。

研究设计与样本

  • 回顾性分析2004年1月至2024年8月在本机构评估的217例Castleman病患者。
  • 按解剖分布分为单中心型、寡中心型和多中心型;人疱疹病毒8阴性多中心型称为特发性多中心型,进一步分为TAFRO、特发性浆细胞性淋巴结病(IPL)和未另作指定亚型。
  • 采用log-rank检验比较生存概率。

主要发现

  • 总体中57%为单中心型,20%为寡中心型,23%为特发性多中心型。
  • 寡中心型和特发性多中心型患者较单中心型更常出现全身症状。
  • 寡中心型和特发性多中心型的无事件生存期分别为8.9年和2.3年,均显著短于单中心型(未达到;P<.001和P<.02)。
  • 在特发性多中心型亚型中,特发性多中心型-浆细胞型的无事件生存期长于特发性多中心型-TAFRO(P=.02),随访期间无死亡。

临床怎么用

  • 作者认为,根据疾病亚型制定治疗策略并警惕寡中心型进展可能改善Castleman病患者的生存结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Castleman disease (CD) is a heterogeneous group of lymphoproliferative disorders anatomically classified by distribution (unicentric CD [UCD], oligocentric CD [oligoCD], or multicentric CD [MCD]). Human herpes virus 8-negative MCD is called idiopathic MCD (iMCD), which includes clinical subtypes with varying phenotypes and responses: TAFRO (thrombocytopenia, anasarca, fever, renal dysfunction and/or reticulin fibrosis, and organomegaly), IPL (idiopathic plasmacytic lymphadenopathy), and not otherwise specified. OligoCD has recently emerged as an intermediate form between UCD and MCD, with unclear clinical behavior, and IPL has not been validated in a Western cohort. We retrospectively analyzed 217 patients with CD evaluated at our institution between January 2004 and August 2024. Survival probabilities were compared using log-rank tests. Overall, 57% had UCD, 20% had oligoCD, and 23% had iMCD. Patients with oligoCD and iMCD more frequently exhibited systemic symptoms than those with UCD. Patients with oligoCD and iMCD had significantly shorter event-free survival (EFS) of 8.9 and 2.3 years, respectively, than those with UCD (not reached; P< .001 and P< .02). Among iMCD subtypes, iMCD-IPL demonstrated a longer EFS than iMCD-TAFRO (P = .02), with no deaths during the follow-up periods. The results validate oligoCD and iMCD-IPL as new subtypes in this Western cohort. The survival outcome in oligoCD was intermediate between UCD and iMCD, with only a subset of patients with oligoCD requiring systemic therapy. iMCD-IPL had a favorable survival outcome in this US cohort, similar to what has been reported in non-Western countries. Tailoring treatment strategies to disease subtypes and vigilant monitoring of oligoCD for progression may improve survival outcomes in CD.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Nishimura Y, Habermann T, Gertz M, et al. Comprehensive analysis of subtype-specific outcomes and management in Castleman disease: a 20-year cohort study. Blood Adv. 2026. PMID: 41441992. doi:10.1182/bloodadvances.2025018324

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。